相似文献
1
Controversy regarding ACE inhibitors / ARBs in COVID-19.
Rev Esp Cardiol (Engl Ed). 2020 Jun;73(6):516. doi: 10.1016/j.rec.2020.04.004. Epub 2020 Apr 15.
2
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?
Cardiol Rev. 2020 Jul/Aug;28(4):213-216. doi: 10.1097/CRD.0000000000000319.
3
COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
J Mol Cell Cardiol. 2020 Jul;144:12-14. doi: 10.1016/j.yjmcc.2020.04.026. Epub 2020 Apr 24.
4
The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
Intern Emerg Med. 2020 Aug;15(5):759-766. doi: 10.1007/s11739-020-02364-6. Epub 2020 May 19.
5
The role of ACEIs/ARBs in COVID-19: Friend or foe?
Med Hypotheses. 2020 Sep;142:109810. doi: 10.1016/j.mehy.2020.109810. Epub 2020 May 5.
6
SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs.
Hypertens Res. 2020 Sep;43(9):985-986. doi: 10.1038/s41440-020-0488-z. Epub 2020 Jun 10.
7
[ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
G Ital Cardiol (Rome). 2020 May;21(5):321-327. doi: 10.1714/3343.33127.
8
Drugs and the renin-angiotensin system in covid-19.
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
9
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
Elife. 2020 Apr 6;9:e57278. doi: 10.7554/eLife.57278.
10
Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
Bol Med Hosp Infant Mex. 2020;77(5):274-281. doi: 10.24875/BMHIM.20000158.
引用本文的文献
1
Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19.
Front Pharmacol. 2024 Jul 12;15:1414406. doi: 10.3389/fphar.2024.1414406. eCollection 2024.
2
Design and study of bioisosteric analogues of the drug Molnupiravir as potential therapeutics against SARS-COV-2: an in silico approach.
In Silico Pharmacol. 2023 Dec 2;12(1):1. doi: 10.1007/s40203-023-00171-3. eCollection 2024.
3
Role of the renin-angiotensin system in the development of COVID-19-associated neurological manifestations.
Front Cell Neurosci. 2022 Sep 16;16:977039. doi: 10.3389/fncel.2022.977039. eCollection 2022.
4
The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects.
Biophys Chem. 2022 Sep;288:106824. doi: 10.1016/j.bpc.2022.106824. Epub 2022 May 12.
5
Effect of Underlying Cardiovascular Disease on the Prognosis of COVID-19 Patients; a Sex and Age-Dependent Analysis.
Arch Acad Emerg Med. 2021 Sep 30;9(1):e65. doi: 10.22037/aaem.v9i1.1363. eCollection 2021.
6
Integrating heterogeneous data to facilitate COVID-19 drug repurposing.
Drug Discov Today. 2022 Feb;27(2):558-566. doi: 10.1016/j.drudis.2021.10.002. Epub 2021 Oct 16.
7
Predictors of severity and development of critical illness of Egyptian COVID-19 patients: A multicenter study.
PLoS One. 2021 Sep 23;16(9):e0256203. doi: 10.1371/journal.pone.0256203. eCollection 2021.
8
Fulminant hepatic failure in a patient testing re-positive for SARS-CoV-2: a case report.
Int J Emerg Med. 2021 Apr 21;14(1):24. doi: 10.1186/s12245-021-00349-6.
9
COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?
Thromb Res. 2020 Dec;196:143-151. doi: 10.1016/j.thromres.2020.08.039. Epub 2020 Aug 27.
本文引用的文献
1
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.
2
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.
Sci China Life Sci. 2020 Mar;63(3):457-460. doi: 10.1007/s11427-020-1637-5. Epub 2020 Jan 21.
3
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
Nat Med. 2005 Aug;11(8):875-9. doi: 10.1038/nm1267. Epub 2005 Jul 10.
4
Angiotensin-converting enzyme 2 protects from severe acute lung failure.
Nature. 2005 Jul 7;436(7047):112-6. doi: 10.1038/nature03712.
Zotero 插件